Don't Set Special IP Rules For 'Skinny Labels,' Justices Told
Drugmakers, industry groups, hospitals and scholars have urged the U.S. Supreme Court to uphold a decision letting a patent suit proceed over a generic drug using a so-called skinny label, saying...To view the full article, register now.
Already a subscriber? Click here to view full article